In-Depth Platelet Proteomic Analysis in Various Dementia Stages: Unveiling Biomarkers for Alzheimer's Disease

ABSTRACT: Early detection of Alzheimer’s disease (AD) can provide an effective scheme to prevent the disease progression. Studies have shown that blood platelets are a useful peripheral source for AD diagnosis. Identifying proteomics-based platelet biomarkers of mild cognitive impairment (MCI) and AD related to amyloid peptide (A) deposition, which remains largely unexplored, is valuable. This study compared four groups from 18 human participants. subjective memory impairment (SMI, n = 4) as cognitive normal control, MCI without A deposition (MCI-A(), n = 5), MCI with A deposition (MCI-A(), n = 5), and AD (n = 4). We performed in-depth platelet protein profiling using high-throughput LC–MS/MS with tandem mass tag (TMT) labeling.MCI-A(), MCI-A(), and AD in comparison to SMI. Hierarchical clustering analysis revealed seven different patterns of proteomic alterations among functional network and gene ontology (GO) enrichment showed a distinct feature of each cluster specific processes such as platelet activation, AD, and apoptotic signaling pathways. In particular, our data indicated that upregulated proteins in MCI-A() and AD are associated with endomembrane system organization. Moreover, we determined the relative abundance of multiple protein candidates that significantly changed in MCI-A() and AD compared to SMI and MCI-A(). Our data demonstrated that several platelet proteins, including ATP6V0C, AP4B1, RAB2B, PSMD9, FKBP1B, and mTOR, can be key molecular targets for predicting AD at the stage of MCI with A deposition and provide insights into amyloid-related neurodegeneration.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Platelet

SUBMITTER: Andrew Kim  

LAB HEAD: Kwang Pyo Kim

PROVIDER: PXD067460 | Pride | 2026-05-25

REPOSITORIES: Pride